Results 101 to 110 of about 2,875 (114)

Donanemab in Early Alzheimer’s Disease

New England Journal of Medicine, 2021
Stephen Salloway, Liana G. Apostolova, Miroslaw Brys   +2 more
exaly   +2 more sources

Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials

Healthcare, 2023
Azza Sarfraz, Ivan Cherrez Ojeda, Zouina Sarfraz   +2 more
exaly  

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

JAMA - Journal of the American Medical Association, 2023
Douglas W Scharre, Lon S Schneider, Hisatomo Kowa   +2 more
exaly  

Still Grasping at Straws: Donanemab in Alzheimer’s Disease

Expert Opinion on Investigational Drugs, 2021
exaly  

Donanemab: Appropriate Use Recommendations

journal of prevention of Alzheimer's disease, The
Dennis J. Selkoe, Suzanne B Hendrix, Stephen Salloway   +2 more
exaly  

TRAILBLAZER-ALZ 4: A Phase 3 Trial Comparing Donanemab With Aducanumab on Amyloid Plaque Clearance in Early, Symptomatic Alzheimer's Disease

Alzheimer's and Dementia
Emily C Collins, John R Sims, Andrew Pain   +2 more
exaly  

Pharmacokinetic Evaluation of Donanemab for the Treatment of Alzheimer’s

Expert Opinion on Drug Metabolism and Toxicology
George T Grossberg, Bret David Silverglate   +1 more
exaly  

Comparative Efficacy, Tolerability and Acceptability of Donanemab, Lecanemab, Aducanumab and Lithium on Cognitive Function in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Network Meta-Analysis

Ageing Research Reviews
Itsuki Terao, Wakako Kodama
exaly  

Donanemab for Alzheimer’s Disease: From Preclinical Research to the Clinical Application

Expert Review of Neurotherapeutics
Lutz Froelich, Richard Dodel
exaly